Denver and Marshall scores successfully predict susceptibility to multiple independent infections in trauma patients

Marianna Almpani¹,2, Amy Tsurumi¹,2,3, Thomas Peponis¹, Yashoda V. Dhole¹, Laura F. Goodfield¹, Ronald G. Tompkins¹,2, Laurence G. Rahme¹,2,3*

¹ Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 2 Shriners Hospitals for Children-Boston, Boston, Massachusetts, United States of America, 3 Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America

* E-mail: rahme@moltbio.mgh.harvard.edu

Abstract

Trauma patients are at risk of repeated hospital-acquired infections, however predictive scores aiming to identify susceptibility to such infections are lacking. The objective of this study was to investigate whether commonly employed disease-severity scores can successfully predict susceptibility to multiple independent infectious episodes (MIIEs) among trauma patients. A secondary analysis of data derived from the prospective, longitudinal study “Inflammation and the Host Response to Injury” (“Glue Grant”) was performed. 1,665 trauma patients, older than 16, were included. Patients who died within seven days from the time of injury were excluded. Five commonly used disease-severity scores [Denver, Marshall, Acute Physiology and Chronic Health Evaluation II (APACHE II), Injury Severity Score (ISS), and New Injury Severity Score (NISS)] were examined as independent predictors of susceptibility to MIIEs. The latter was defined as two or more independent infectious episodes during the index hospital stay. Multivariable logistic regression was used for the statistical analysis. 22.58% of the population was found to be susceptible to MIIEs. Denver and Marshall scores were highly predictive of the MIIE status. For every 1-unit increase in the Denver or the Marshall score, there was a respective 15% ( Odds Ratio: 1.15; 95% CI: 1.07–1.24; p < 0.001) or 16% (Odds Ratio: 1.16; 95% CI: 1.09–1.24; p < 0.001) increase in the odds of MIIE occurrence. APACHE II, ISS, and NISS were not independent predictors of susceptibility to MIIEs. In conclusion, the Denver and Marshall scores can reliably predict which trauma patients are prone to MIIEs, prior to any clinical sign of infection. Early identification of these individuals would potentially allow the implementation of rapid, personalized, preventative measures, thus improving patient outcomes and reducing healthcare costs.

Introduction

Traumatic injury has long been identified as one of the leading causes of morbidity and mortality worldwide [1]. The rates of hospital-acquired infections are high in the trauma...
recipient’s IRB letter of approval and IRB-approved protocol or application. In the event that an individual or institution does not have an internal IRB or ethical committee, the individual is required to obtain IRB approval from an independent IRB, such as the Western IRB (WIRB). Upon approval of the Steering Committee, the requested data will be viewable under the recipient’s user name and password. Investigators that are interested to access the database can go to the Glue Grant public web site at http://www.gluegrant.org/ for a link to information about TRDB Con. We confirm that other researchers would be able to access the data set in the same manner as the authors, and the authors did not have any special access privileges that others would not have.

**Funding:** The investigators acknowledge the contribution of the Inflammation and the Host Response to Injury Large-Scale Collaborative Project Award 5U54GM062119 to RGT from the National Institute of General Medical Sciences. Shriners Hospitals Research Fellowship #84313. AT was supported by the Shriners Hospitals Research Fellowship #84293. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** L.G.R. has a financial interest in Spero Therapeutics, a company developing therapies for the treatment of bacterial infections. L.G.R.’s financial interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. The rest of the authors declare that no competing interests exist.

population and such infections lead to a substantial increase in the hospital length of stay and associated costs [2–4]. Despite the plethora of available scoring systems that quantify the severity of trauma and organ failure and predict mortality following traumatic injury, only a limited number of studies have looked into the ability of these tools to calculate the risk of infections in trauma patients [5–8]. Frequently, these studies have concluded contradictory findings; some have shown that these scores can successfully predict the risk of hospital acquired infections [7, 8], whereas others have concluded a lack of predictive value in the trauma setting [5, 6]. Thus, the role of disease-severity scores in predicting infections following trauma is yet to be determined. More importantly, the existing studies do not take into account the fact that some patients might be susceptible to multiple infections, hence at risk of developing multiple independent infectious episodes (MIIEs) during their hospital stay. Patients that are prone to MIIEs represent a different cohort than those who develop either one or no infections. Identifying susceptibility to multiple infections could prove paramount and practically alter the management of such patients [9–11].

This study aims to evaluate whether organ dysfunction and trauma severity, assessed by commonly employed disease-severity scoring systems, could successfully predict patient susceptibility to MIIEs during their hospital stay. Early identification of trauma patients that are susceptible to MIIEs prior to any clinical evidence of infection, would allow for timely prophylactic interventions. Therefore, these scoring systems could prove to be valuable tools in our efforts to (i) prevent infections and the ensuing adverse and often life-threatening, complications; (ii) implement antibiotic stewardship in the era of rapidly emerging resistance to most current antimicrobial therapeutics; (iii) minimize the ever-rising health care costs.

**Methods**

This study is a retrospective review of clinical data derived from the “Inflammation and the host response to injury” study (“Glue Grant”). Permission for this secondary use of the deidentified data was obtained from our Institutional Review Board (MGH IRB protocol 2008-P-000629/1).

“Inflammation and the host response to injury” is a multicenter, prospective, longitudinal study, that registered acutely injured patients, who were hospitalized at seven Level 1 trauma centers across the United States between 2003 and 2009. Among 1,937 patients in the Glue Grant trauma database with available relevant clinical data, 1,892 were adult (> 16 years) patients. From these, 227 patients died within 7 days from the date of injury and were excluded. Therefore, a population of 1,665 adult trauma patients was used for the analysis.

Eligible patients were stratified based on their susceptibility to multiple infections (suffered ≥ 2 independent infectious episodes), according to a previously developed decision tree [11]. Based on this previously published algorithm, the time of infection, the type of illness, and the microorganism causing the infection are the necessary elements to determine whether an infectious episode is independent of the other infections that a given patient has suffered, as described in [11]. Those with 2 or more independent infections were considered to be susceptible to MIIEs, and those who presented with either none or one infection were classified as non-susceptible to MIIEs. Each of the independent infectious episodes was classified as a surgical site infection (SSI), or as a non-SSI. Patients who experienced multiple infectious events presented with SSIs alone, non-SSIs alone, or a combination of both.

The definitions of the clinical outcomes of the patients were based on the guidelines outlined by the Glue Grant Consortium [12]. Accordingly, patients were deemed to have non-SSIs if they were diagnosed with pneumonia, ventilator-associated pneumonia, bloodstream
infections, catheter-related bloodstream infections, urinary tract infections, meningitis, sinusitis, endocarditis, cholecystitis, empyema, and/or pseudomembranous colitis. SSIs included superficial incisional (referring to skin, or subcutaneous tissue infections), deep incisional (referring to infections of deep soft tissues, such as fascial and muscle layers), and organ/space SSIs [12].

Five commonly employed disease-severity scoring systems were captured in the Glue Grant trauma database and were compared between the case and the control groups. More specifically, we utilized (i) the Injury Severity Score (ISS), (ii) the New Injury Severity Score (NISS), (iii) the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, (iv) the Denver score (S1 Table), and (v) the Marshall score (S2 Table; for the purposes of the Glue Grant, a modified Marshall score, excluding the neurologic component of the classic Marshall score, was utilized) [13, 14].

A univariate analysis was performed to identify possible risk factors that could contribute to the MIIE susceptibility status. We assessed all the available variables in the database including demographics [age, gender, race, body mass index (BMI)], comorbidities, tobacco smoking, alcohol and intravenous drug abuse, injury characteristics (type and mechanism), the elapsed time from the time of the injury to arrival in the Emergency Room (ER), the lowest systolic blood pressure (SBP) while the patient was in the ER, the hemoglobin level at the time of arrival in the ER, the ICU length of stay, and ICU interventions, if applicable (tracheostomy, length of mechanical ventilation). The Mann-Whitney U test was used to compare continuous variables, presented as the median ± interquartile range (25th to 75th percentile) and the chi-square was used for the comparison of categorical variables, presented as frequencies and percentages. A p-value of less than 0.05 was considered statistically significant.

Stepwise logistic regression analysis was subsequently performed. Variables that achieved a p-value of <0.2 were entered in the regression model. Multivariable analysis was performed with one scoring system at a time to determine the predictive value for each score. Adjusted odds ratios (aORs) and 95% confidence intervals (95% CI) were calculated. Statistical analysis was performed using the STATA software (version 13.1).

Results

Demographics and clinical characteristics of the population
The characteristics of the 1,665 adult trauma patients included in the study are displayed in Table 1. The median age of the cohort was 42.4 years, while the median BMI was 28.2. Approximately two thirds of the population were males (66.55%), and almost 9 out of 10 were of white race (89.37%). 28.95% were smokers, 13.27% admitted chronic alcohol abuse, while only 2.22% were intravenous drug users. Almost all patients had suffered blunt injuries alone (99.1%), with only a small number of subjects suffering a combination of both blunt and penetrating trauma (0.9%), while none exhibited penetrating injuries alone. The vast majority of the patients (84.74%) were involved in a Motor Vehicle Collision (MVC). The subjects were transferred to the hospital within a median of 1.9 hours. For those that fully recovered and were eventually discharged (1,582 patients), the median length of stay in the hospital was 21 days. 83 patients died. The latter had a median survival (hospital length of stay) of 9 days. All patients were admitted for at least one day in the ICU, with the median length of stay being 14.3 days.

Approximately one fifth of the subjects suffered two or more independent infectious episodes (22.58%) and were thus deemed to be susceptible to MIIEs. Out of the 376 susceptible to MIIEs patients, 54.26% presented with non-SSIs alone, 2.39% presented with SSIs alone, while 43.35% presented with both non-SSIs and SSIs (Fig 1A). From the non-susceptible to MIIEs
Table 1. Characteristics of the population (n = 1,665) and comparison of patients who were susceptible to multiple infections to those who were not.

| Variable                        | Data                  | Susceptibility Yes (n = 376) | Susceptibility No (n = 1,289) | p-value |
|---------------------------------|-----------------------|------------------------------|-------------------------------|---------|
| Age (in years), median (IQR)    | 42.4 (26–55)          | 41.64 (26–54)                | 42.69 (27–55)                 | 0.373   |
| BMI, median (IQR)               | 28.2 (23.88–31.25)    | 29.09 (24.21–32.42)         | 27.97 (23.79–30.93)           | 0.008   |
| Gender, n (%)                   |                       |                              |                               |         |
| Males                           | 1,108 (66.55)         | 244 (64.89)                  | 864 (67.03)                   | 0.440   |
| Females                         | 557 (33.45)           | 132 (35.11)                  | 425 (32.97)                   |         |
| Race, n (%)                     |                       |                              |                               |         |
| White                           | 1,488 (89.37)         | 333 (88.56)                  | 1,155 (89.60)                 | 0.707   |
| Asian                           | 37 (2.22)             | 6 (1.60)                     | 31 (2.40)                     |         |
| African American                | 101 (6.07)            | 27 (7.18)                    | 74 (5.74)                     |         |
| Other                           | 4 (0.24)              | 0 (0.00)                     | 4 (0.31)                      |         |
| American Indian                 | 21 (1.26)             | 6 (1.60)                     | 15 (1.16)                     |         |
| Pacific Islanders               | 7 (0.42)              | 2 (0.53)                     | 5 (0.39)                      |         |
| Unknown                         | 7 (0.42)              | 2 (0.53)                     | 5 (0.39)                      |         |
| Hypertension, n (%)             | 259 (15.56)           | 60 (15.96)                   | 199 (15.44)                   | 0.807   |
| Myocardial Infarction, n (%)    | 48 (2.88)             | 10 (2.66)                    | 38 (2.95)                     | 0.769   |
| Congestive Heart Failure, n (%) | 25 (1.5)              | 4 (1.06)                     | 21 (1.63)                     | 0.428   |
| Atrial Tachyarrhythmias, n (%)  | 28 (1.68)             | 11 (2.93)                    | 17 (1.32)                     | 0.033   |
| Ventricular Tachyarrhythmias, n (%) | 4 (0.24)          | 0 (0.00)                     | 4 (0.31)                      |         |
| Peripheral Vascular Disease, n (%) | 17 (1.02)             | 6 (1.60)                     | 11 (0.85)                     | 0.208   |
| Cerebrovascular Disease, n (%)  | 44 (2.64)             | 15 (3.99)                    | 29 (2.25)                     | 0.064   |
| Dementia, n (%)                 | 16 (0.96)             | 2 (0.53)                     | 14 (1.09)                     | 0.332   |
| Seizure, n (%)                  | 45 (2.70)             | 8 (2.13)                     | 37 (2.87)                     | 0.435   |
| Previous Traumatic Brain Injury, n (%) | 28 (1.68)             | 6 (1.60)                     | 22 (1.71)                     | 0.883   |
| Parkinson’s Disease, n (%)      | 1 (0.06)              | 0 (0.00)                     | 1 (0.08)                      | 0.589   |
| Chronic Pulmonary Disease, n (%) | 54 (3.24)             | 14 (3.72)                    | 40 (3.10)                     | 0.550   |
| Rheumatologic Disease, n (%)    | 24 (1.44)             | 3 (0.80)                     | 21 (1.63)                     | 0.234   |
| Peptic Ulcer Disease, n (%)     | 21 (1.26)             | 6 (1.60)                     | 15 (1.16)                     | 0.509   |
| Liver Disease, n (%)            | 57 (3.42)             | 14 (3.72)                    | 43 (3.34)                     | 0.716   |
| Diabetes, n (%)                 | 122 (7.33)            | 26 (6.91)                    | 96 (7.45)                     | 0.727   |
| Hypothyroidism, n (%)           | 45 (2.70)             | 10 (2.66)                    | 35 (2.72)                     | 0.953   |
| Hyperthyroidism, n (%)          | 4 (0.24)              | 0 (0.00)                     | 4 (0.31)                      | 0.279   |
| Chronic Renal Dysfunction, n (%) | 11 (0.66)             | 7 (1.86)                     | 4 (0.31)                      | 0.001   |
| History of Malignancy, n (%)    | 54 (3.24)             | 13 (3.46)                    | 41 (3.18)                     | 0.790   |
| Metastatic Solid Tumor, n (%)   | 4 (0.24)              | 2 (0.53)                     | 2 (0.16)                      | 0.189   |
| Coagulopathy (congenital or acquired), n (%) | 7 (0.42)           | 5 (1.33)                     | 2 (0.16)                      | 0.002   |
| Smoker, n (%)                   | 482 (28.95)           | 104 (27.66)                  | 378 (29.33)                   | 0.531   |
| Chronic Alcoholism, n (%)       | 221 (13.27)           | 53 (14.10)                   | 168 (13.03)                   | 0.593   |
| Intravenous Drug Use, n (%)     | 37 (2.22)             | 7 (1.86)                     | 30 (2.33)                     | 0.590   |
| Psychiatric Disorder, n (%)     | 179 (10.75)           | 46 (12.23)                   | 133 (10.32)                   | 0.291   |
| Recent Solid Organ Transplant, n (%) | 5 (0.30)             | 2 (0.53)                     | 3 (0.23)                      | 0.351   |
| Chemotherapy or Radiotherapy within 30 days, n (%) | 2 (0.12)          | 0 (0.00)                     | 2 (0.16)                      | 0.445   |
| Asthma, n (%)                   | 86 (5.17)             | 22 (5.85)                    | 64 (4.97)                     | 0.495   |
| Hypercholesterolemia / Hyperlipidemia, n (%) | 98 (5.89)           | 22 (5.85)                    | 76 (5.90)                     | 0.974   |
| Prior CABG, n (%)               | 58 (3.48)             | 15 (3.99)                    | 43 (3.34)                     | 0.543   |
| Cardiovascular Disease, n (%)   | 16 (0.96)             | 2 (0.53)                     | 14 (1.09)                     | 0.332   |
| Injury Type, n (%)              |                       |                              |                               |         |
| Blunt                           | 1,650 (99.10)         | 373 (99.20)                  | 1,277 (99.07)                 | 0.810   |
| Blunt and penetrating           | 15 (0.90)             | 3 (0.80)                     | 12 (0.93)                     |         |

(Continued)
patients, 60.28% exhibited no infections (Fig 1A), while among those with one infection, 84.18% presented with a non-SSI alone, and 15.82% presented with an SSI alone (Fig 1A). Pneumonia was the most common type of non-SSIs among both susceptible (73.40%) and non-susceptible to MIIEs patients (48.63%) (Fig 1B). Bloodstream and urinary infections followed in both groups, with 41.22% and 40.96% of the susceptible to MIIEs patients developing bloodstream and urinary infections respectively (Fig 1B), and 22.46% and 13.09% of the patients with 1 infection episode presenting with a urinary or bloodstream infection respectively (Fig 1B). The most usual locations for SSIs in both groups were the abdomen/pelvis area and the lower extremities, with abdomen/pelvis infections taking the lead in the susceptible to MIIEs group (23.40%) and lower extremity infections being the majority in the non-susceptible to MIIEs patients with 1 infection (7.03%) (Fig 1C).

Table 1. (Continued)

| Variable                              | Data     | Susceptibility Yes (n = 376) | Susceptibility No (n = 1289) | p-value |
|---------------------------------------|----------|------------------------------|------------------------------|---------|
| Injury Mechanism, n (%)               | Fall     | 142 (8.53)                   | 33 (8.78)                    | 109 (8.46) |
|                                       | Machinery| 36 (2.16)                    | 7 (1.86)                     | 29 (2.25) |
|                                       | MVC      | 1,411 (84.74)                | 323 (85.90)                  | 1,088 (84.41) |
|                                       | Assault  | 44 (2.64)                    | 8 (2.13)                     | 36 (2.79) |
|                                       | Other    | 32 (1.92)                    | 5 (1.33)                     | 27 (2.09) |
| Blood transfusion prior to blood sample collection, n (%) | 438 (26.31) | 94 (25.00)                  | 344 (26.69)                  | 0.513 |
| ICU tracheostomy, n (%)               | 432 (25.95) | 189 (50.27)                 | 243 (18.85)                  | <0.001 |
| ICU Days, median (IQR)                | 14.3 (5–19) | 25.24 (16–31)               | 11.06 (4–15)                 | <0.001 |
| ICU Ventilation Days, median (IQR)    | 10.5 (3–15) | 19.77 (11–25)               | 7.77 (2–11)                  | <0.001 |
| Time from injury to ER arrival, median (IQR) | 1.9 (0.8–2.7) | 1.71 (0.7–2.1)              | 1.99 (0.8–2.8)               | 0.001 |
| Lowest SBP at ER, median (IQR)        | 85.5 (72–97) | 81.73 (69.5–94)             | 86.62 (74–98)                | <0.001 |
| Initial Hemoglobin at ER, median (IQR)| 11.47 (9.8–13.2) | 11.10 (9.3–13)             | 11.58 (10–13.2)           | 0.001 |
| Major Procedure, n (%)                | 1,569 (94.23) | 361 (96.01)                | 1,208 (93.72)                | 0.093 |
| Max Marshal Score, median (IQR)       | 5.16 (3.29–6.64) | 6.90 (5.21–8.28)          | 4.66 (2.981–6.01)          | <0.001 |
| Max Denver Score, median (IQR)        | 2.09 (0–3)   | 3.32 (2–5)                  | 1.74 (0–3)                   | <0.001 |
| APACHE II Score, median (IQR)         | 27.75 (24–33) | 30.83 (27–35)              | 26.86 (23–32)               | <0.001 |
| ISS, median (IQR)                     | 31.9 (22–41) | 35.66 (27–43)              | 30.81 (22–41)               | <0.001 |
| NISS, median (IQR)                    | 37.4 (27–48) | 41.78 (34–50)              | 36.17 (27–45)               | <0.001 |

n, number of observations; IQR, interquartile range (25th to 75th percentile); BMI, body mass index; CABG, coronary artery bypass graft; MVC, motor vehicle collision; ICU, intensive care unit; ER, emergency room; SBP, systolic blood pressure; APACHE II, acute physiology and chronic health evaluation II score; ISS, injury severity score; NISS, new injury severity score.

https://doi.org/10.1371/journal.pone.0232175.001

Evaluation of severity scores as independent predictors for MIIE susceptibility

The two multivariable analysis models including (a) the Denver score (Table 2), and (b) the Marshall score (Table 3), show that both scores are independent predictors of susceptibility to
MIIEs (aOR = 1.15, p < 0.001, 95% CI = 1.07–1.24 for the Denver score; aOR = 1.16, p < 0.001, 95% CI = 1.09–1.24 for the Marshall score), while, in both models, ICU length of stay (aOR = 1.07, p < 0.001, 95% CI = 1.03–1.10 in both models), and initial hemoglobin level upon arrival to the ER (aOR = 0.93, p = 0.010, 95% CI = 0.89–0.98 in the Denver model; aOR = 0.94, p = 0.015, 95% CI = 0.89–0.99 in the Marshall model) were also independent predictors of predisposition to MIIEs. Importantly, these results show that the odds of a patient to develop MIIEs increases by 15% with each unit increase in the Denver score and by 16% with each unit increase in the Marshall score.

Variables that were removed from the stepwise logistic regression, because of p-values > 0.2 included: age, gender, race, hypertension, myocardial infarction, congestive heart failure, ventricular tachyarrhythmias, peripheral vascular disease, dementia, seizure, previous traumatic brain injury, Parkinson’s disease, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, liver disease, diabetes, hypothyroidism, hyperthyroidism, history of malignancy, smoking status, chronic alcoholism, intravenous drug use, psychiatric disorder, resent solid organ transplant, chemotherapy or radiotherapy within 30 days, asthma, hypercholesterolemia/hyperlipidemia, prior CABG, cardiovascular disease, injury type, injury mechanism, blood transfusion prior to blood sample collection.
Variables that were removed from the stepwise logistic regression, because of p-values > 0.2 included: age, gender, race, hypertension, myocardial infarction, congestive heart failure, ventricular tachyarrhythmias, peripheral vascular disease, dementia, seizure, previous traumatic brain injury, Parkinson’s disease, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, liver disease, diabetes, hypothyroidism, hyperthyroidism, history of malignancy, smoking status, chronic alcoholism, intravenous drug use, psychiatric disorder, resent solid organ transplant, chemotherapy or radiotherapy within 30 days, asthma, hypercholesterolemia/hyperlipidemia, prior CABG, cardiovascular disease, injury type, injury mechanism, blood transfusion prior to blood sample collection.

Table 2. Multivariable analysis to find independent predictors of susceptibility to multiple infections (Denver score).

| Variable                              | Odds Ratio | 95% Confidence Interval   | p-value |
|---------------------------------------|------------|---------------------------|---------|
| Denver score                          | 1.15       | 1.07–1.24                 | <0.001  |
| BMI                                   | 1.00       | 0.98–1.02                 | 0.950   |
| Atrial Tachyarrhythmias               | 1.34       | 0.51–3.57                 | 0.551   |
| Cerebrovascular Disease               | 1.28       | 0.59–2.78                 | 0.533   |
| Metastatic Solid Tumor                | 3.12       | 0.42–23.18                | 0.267   |
| Chronic Renal Dysfunction             | 2.86       | 0.67–12.18                | 0.155   |
| Coagulopathy congenital or acquired   | 4.79       | 0.66–34.54                | 0.120   |
| ICU Days                              | 1.07       | 1.03–1.10                 | <0.001  |
| ICU Ventilation Days                  | 1.02       | 0.99–1.06                 | 0.191   |
| ICU tracheostomy                      | 1.25       | 0.90–1.75                 | 0.187   |
| Time from injury to ER arrival        | 0.92       | 0.84–1.01                 | 0.072   |
| Lowest SBP at the ER                  | 1.00       | 0.99–1.01                 | 0.876   |
| Initial Hemoglobin value at the ER    | 0.93       | 0.89–0.98                 | 0.010   |
| Major Procedures                      | 1.73       | 0.90–3.34                 | 0.102   |

BMI, body mass index; ICU, intensive care unit; ER, emergency room; SBP, systolic blood pressure.

https://doi.org/10.1371/journal.pone.0232175.t002

Table 3. Multivariable analysis to find independent predictors of susceptibility to multiple infections (Marshall).

| Variable                              | Odds Ratio | 95% Confidence Interval   | p-value |
|---------------------------------------|------------|---------------------------|---------|
| Marshall score                        | 1.16       | 1.09–1.24                 | <0.001  |
| BMI                                   | 1.00       | 0.98–1.02                 | 0.820   |
| Atrial Tachyarrhythmias               | 1.33       | 0.51–3.46                 | 0.561   |
| Cerebrovascular Disease               | 1.28       | 0.59–2.78                 | 0.533   |
| Metastatic Solid Tumor                | 2.5        | 0.34–18.19                | 0.370   |
| Chronic Renal Dysfunction             | 2.98       | 0.69–12.88                | 0.144   |
| Coagulopathy congenital or acquired   | 4.76       | 0.66–34.51                | 0.123   |
| ICU Days                              | 1.07       | 1.03–1.10                 | <0.001  |
| ICU Ventilation Days                  | 1.02       | 0.98–1.06                 | 0.305   |
| ICU tracheostomy                      | 1.30       | 0.93–1.81                 | 0.129   |
| Time from injury to ER arrival        | 0.92       | 0.84–1.00                 | 0.060   |
| Lowest SBP at the ER                  | 1.00       | 0.99–1.01                 | 0.855   |
| Initial Hemoglobin value at the ER    | 0.94       | 0.89–0.99                 | 0.015   |
| Major Procedures                      | 1.60       | 0.83–3.08                 | 0.162   |

BMI, body mass index; ICU, intensive care unit; ER, emergency room; SBP, systolic blood pressure.

https://doi.org/10.1371/journal.pone.0232175.t003
On the contrary, APACHE II, ISS, and NISS in their respective multivariable analysis models (S3–S5 Tables) failed to independently predict which patients would be more prone to MIIEs (aOR = 1.02, p = 0.097, 95% CI = 1.00–1.04 for APACHE II; aOR = 1.01, p = 0.321, 95% CI = 0.99–1.02 for ISS; aOR = 1.01, p = 0.131, 95% CI = 1.00–1.02 for NISS), with possible confounding factors in all three models being: a) the ICU length of stay (aOR = 1.07, p<0.001, 95% CI = 1.03–1.10 in the APACHE II model; aOR = 1.06, p<0.001, 95% CI = 1.03–1.10 in the ISS and the NISS models), b) the ICU ventilation duration (aOR = 1.04, p = 0.043, 95% CI = 1.00–1.07 in the APACHE II model; aOR = 1.04, p = 0.026, 95% CI = 1.00–1.08 in the ISS model; aOR = 1.04, p = 0.031, 95% CI = 1.00–1.08 in the NISS model), and the initial hemoglobin level upon arrival to the ER (aOR = 0.94, p = 0.021, 95% CI = 0.89–0.99 in the APACHE II model; aOR = 0.93, p = 0.008, 95% CI = 0.88–0.98 in the ISS and the NISS models).

Validation of the Denver and Marshall scores’ ability to predict susceptibility to MIIEs among patients with early-assigned scores

While the ISS and NISS scores were assigned to all patients upon hospital admission, and the APACHE II score was assigned within 24h from admission to the Intensive Care Unit (ICU), the Denver and Marshall scores were assigned at different time points for different patients during their recovery course. To control for the time that the Denver and Marshall scores were assigned, subsequent stepwise logistic regression was performed, including only those patients that were assigned a Denver or a Marshall score within 3 days from admission to the hospital. This time point was deemed to be early, as it preceded the average day of infection occurrence, with non-SSIs occurring on average around day 10 and SSIs occurring on average around day 13 of hospitalization. For the validation of our Denver score results, 1282 patients that had an early-assigned Denver score were included, 225 of which were susceptible to MIIEs and 1057 were not. For the validation of our Marshall score results, 1109 patients that had an early-assigned Marshall score were included, 174 of which were susceptible to MIIEs and 935 were not.

The two multivariable analysis models including (a) the Denver score (Table 4), and (b) the Marshall score (Table 5), show that both scores, even when assigned early, are independent predictors of susceptibility to MIIEs (aOR = 1.16, p = 0.014, 95% CI = 1.03–1.31 for the Denver score; aOR = 1.30, p<0.001, 95% CI = 1.15–1.46 for the Marshall score). ICU length of stay continued to be an independent predictor of predisposition to MIIEs in both models (aOR = 1.11, p<0.001, 95% CI = 1.06–1.16 in the Denver model; aOR = 1.09, p<0.001, 95% CI = 1.04–1.15 in the Marshall model). Initial hemoglobin level upon arrival to the ER remained an independent predictor only in the Denver model (aOR = 0.92, p = 0.021, 95% CI = 0.86–0.99).

Discussion

Our study shows that the Denver and Marshall scores, which are used to assess the severity of organ failure in the setting of traumatic injury, can accurately predict susceptibility to MIIEs after trauma, even when assigned much earlier than infection occurrence. These findings suggest that Denver and Marshall could potentially prove to be invaluable tools in predicting the predisposition of trauma patients to MIIEs, before the latter develop any clinical signs of infection, therefore altering the clinical management and leading to implementation of prophylactic measures. Such a predictive tool is currently lacking.

Previous studies investigating the potential of trauma assessment scoring systems to identify patients at increased risk of post-traumatic hospital-acquired infections mainly focused on scores such as APACHE II, ISS and NISS. Hurr and colleagues [6], reported that APACHE II
and ISS did not successfully predict the incidence of infections in trauma patients. All the same, Cheadle and colleagues [5] reported that ISS failed to distinguish between trauma patients with and without infections. These results are in accordance with our findings. Those studies were somewhat limited by their relatively low sample size, as well as by their monocentric nature. Our multicentric study, with more than 1,660 trauma patients, confers sufficient sample size, decreasing the risk of a Type 2 error, thus providing more confidence regarding the aforementioned observations. Furthermore, pediatric patients were included in Hurr’s study [6], despite the fact that the anatomic aspects of pediatric trauma and the physiologic responses to injury in this population significantly differ from those of their adult counterparts [15]. Two more recent prospective studies reported that ISS, NISS and APACHE II directly correlate to the risk of infections in trauma patients, findings that are not consistent with our results [7, 8]. However, in these studies several possible confounders, including those identified in our study, were not accounted for, hence causing a potentially spurious association between APACHE II / ISS / NISS and the presence of infections. Finally, to our best

Table 4. Multivariable analysis to find independent predictors of susceptibility to multiple infections (early-assigned Denver).

| Variable                              | Odds Ratio | 95% Confidence Interval | p-value |
|---------------------------------------|------------|-------------------------|---------|
| Denver score                          | 1.16       | 1.03–1.31               | 0.014   |
| BMI                                   | 1.00       | 0.97–1.03               | 0.999   |
| Atrial Tachyarrhythmias               | 2.06       | 0.63–6.73               | 0.231   |
| Cerebrovascular Disease               | 1.77       | 0.64–4.86               | 0.271   |
| Chronic Renal Dysfunction             | 4.09       | 0.73–22.97              | 0.110   |
| Coagulopathy congenital or acquired   | 1.45       | 0.13–16.35              | 0.762   |
| ICU Days                              | 1.11       | 1.06–1.16               | <0.001  |
| ICU Ventilation Days                  | 1.01       | 0.97–1.06               | 0.617   |
| ICU tracheostomy                      | 1.24       | 0.79–1.95               | 0.351   |
| Time from injury to ER arrival        | 0.99       | 0.88–1.11               | 0.809   |
| Lowest SBP at the ER                  | 1.00       | 0.99–1.01               | 0.606   |
| Initial Hemoglobin value at the ER    | 0.92       | 0.86–0.99               | 0.021   |
| Major Procedures                      | 1.74       | 0.74–4.07               | 0.201   |

Table 5. Multivariable analysis to find independent predictors of susceptibility to multiple infections (early-assigned Marshall).

| Variable                              | Odds Ratio | 95% Confidence Interval | p-value |
|---------------------------------------|------------|-------------------------|---------|
| Marshall score                        | 1.30       | 1.15–1.46               | <0.001  |
| BMI                                   | 0.99       | 0.96–1.02               | 0.424   |
| Atrial Tachyarrhythmias               | 1.42       | 0.33–6.10               | 0.640   |
| Cerebrovascular Disease               | 1.29       | 0.38–4.41               | 0.682   |
| Chronic Renal Dysfunction             | 4.25       | 0.46–39.49              | 0.203   |
| Coagulopathy congenital or acquired   | 4.53       | 0.08–272.30             | 0.470   |
| ICU Days                              | 1.09       | 1.04–1.15               | <0.001  |
| ICU Ventilation Days                  | 1.02       | 0.96–1.07               | 0.579   |
| ICU tracheostomy                      | 1.37       | 0.81–2.31               | 0.241   |
| Time from injury to ER arrival        | 0.92       | 0.81–1.06               | 0.246   |
| Lowest SBP at the ER                  | 1.00       | 1.00–1.01               | 0.337   |
| Initial Hemoglobin value at the ER    | 0.92       | 0.85–0.99               | 0.847   |
| Major Procedures                      | 1.98       | 0.64–6.07               | 0.645   |
knowledge, there is no study investigating the ability of the Marshall and Denver scores, to predict infections in the afore-mentioned population.

Our finding that physiology-based disease-severity scores (i.e., Denver and Marshall), rather than anatomy-based trauma-severity scores (i.e., ISS and NISS) can successfully predict the increased post-traumatic predisposition to MIIEs, conceivably suggests that the post-traumatic susceptibility to MIIEs correlates better with the individual physiologic response to injury, rather than the anatomical severity of the trauma. A seemingly contradictory finding is the fact that even though APACHE II also utilizes physiologic aspects to assess disease severity, this score fails to identify the patients, who are at a higher risk of MIIEs. This observation could potentially be explained by the fact that APACHE II does not account for the hepatic function, aspect that is integrated in both the Denver and the Marshall scores, thus possibly implying a key role for liver dysfunction in the setting of post-injury infections. In support of this consideration, a recent publication describing 4 new sepsis phenotypes, suggests that the “δ phenotype” refers to a subgroup of patients, the members of which are more likely to have hepatic dysfunction, exert significant derangement of their immune responses and are more prone to adverse clinical outcomes [16].

As expected, blood loss after trauma seems to predispose patients to infections, as indicated by the finding that higher hemoglobin levels at the time of admission conferred protection in terms of susceptibility to MIIEs (aOR < 1 for both Denver and Marshall: aOR = 0.93, p = 0.010, 95% CI = 0.89–0.98 for Denver; aOR = 0.94, p = 0.015, 95% CI = 0.89–0.99 for Marshall). Regional hypoxia and the subsequent immediate and persistent depression of various aspects of the immune response has been identified as the underlying mechanism of increased susceptibility to infections in the setting of acute hemorrhage [17]. Similarly, ICU length of stay was another independent predictor of MIIE susceptibility. This result was also anticipated, as it has long been clearly documented that longer duration of ICU stay leads to increased rates of infections [18]. The relationship between MIIEs and length of ICU stays, tracheostomy rates, duration of mechanical ventilation and number of major procedures would arguably be expected to be bidirectional. Therefore, prospective studies would confer higher levels of confidence in delineating this effect.

Our study has a number of strengths. First, an obvious advantage is that our findings derive from the analysis of prospectively collected data of more than 1,660 trauma patients from 7 institutions across the US. This confers sufficient variability and confidence to elucidate significant differences, while effectively identifying erroneous correlations. Second, the longitudinal nature of the data collection for the purposes of the “Glue Grant”, gave us the opportunity to develop an algorithm that effectively identifies patients who are susceptible to multiple infections, which clinically manifests as multiple independent infectious episodes [10, 11]. Though previous studies have interrogated the ability of disease-severity scores to predict the risk of infection, adoption of this decision tree for the first time in the trauma population gives us the opportunity to take this consideration one step further and assess the ability of these scores to identify patients at risk of numerous independent infections, a distinct outcome, with deleterious consequences for the patients and increased cost rates for the hospitals. Third, to our knowledge, no previous study has assessed the Denver and Marshall scores in the setting of post-traumatic infection prognostication, which according to our results, are the only scores that can reliably predict the MIIE occurrence.

Our study carries a few limitations. First, its retrospective nature may raise potential for selection bias. Second, our data derives only from Level 1 trauma centers, thus it may not be generalizable to the patient population of other institutions. Furthermore, given that the anatomical scores (ISS and NISS) are calculated based on the Abbreviated Injury Scale (AIS) that classifies the injuries by body region on a 6-point scale, it is possible that specific components...
might be more important than others. For instance, a traumatic brain injury (TBI) could arguably predispose to more infections compared to a leg injury. However, given that the ISS and NISS are already computed in the Glue Grant database and the individual components are not available, it was impossible to assess the impact of these individual body-part injury scores. Lastly, even though we controlled for a plethora of possible confounding factors that were available in the Glue Grant trauma database, it is possible that there are more lurking variables that were not captured, such as the type and complexity of any operations performed, that could possibly influence the results.

Taken together, our findings could potentially facilitate clinical decision-making by identifying patient subpopulations that are at higher risk of suffering multiple infectious episodes during their hospital stay. Early prognosis, before infections occur, could strategically guide the initiation timing and the duration of antibiotic administration to these patients. It would also allow physicians to implement prophylactic measures, enhance patient nutrition and formulate potent personalized treatment plans for this group of patients, thus protecting those at higher risk of repeated infections during their recovery period. Specifically, patients that are deemed to be susceptible to MIIEs could benefit from the use of central and peripheral IV lines, as well as urine catheters that are coated or impregnated with antimicrobial or antibiotic agents. Studies have shown that their use has been linked to a significant reduction in infection rates [19, 20]. Use of such devices in the wide trauma population would be unnecessarily expensive. However, implementation of this measure in the susceptible to MIIEs population will potentially be cost-effective. Furthermore, strict early replacement of IV lines and urine catheters in this population could be crucial in infection prevention. The time that such devices are removed or replaced differs widely, as replacing them when clinically indicated is more cost-effective than routine replacements every 72-94h [21]. However, the susceptible to MIIEs population could potentially benefit from early replacement, which would subsequently lower their infection rates as well as the related health-care costs. Moreover, implementation of immune-modulatory nutrition has been shown to be beneficial for critically ill patients, therefore it could potentially have a favorable effect in the susceptible to MIIEs population [22]. Finally, given the susceptibility of these patients to MIIEs, taking transmission-based precautions (contact, droplet and airborne) that are not used in the wide trauma population, could aid towards limiting the exposure of these patients to infectious agents. Such an approach would (i) reduce the transmission of multi-drug resistant microbes, (ii) promote antibiotic stewardship, (iii) prevent hospital-acquired infections with the subsequently high mortality and morbidity rates, (iv) shorten hospital length of stay, and (v) drastically reduce the cost of care. Further research combining these clinical-characteristic-based prediction models with gene expression profiling from blood samples of trauma patients could potentially confer even higher levels of confidence in our effort to predict which patients are susceptible to multiple infections. This combination could offer a precision medicine approach that would have the potential not only to limit infections before their onset, but also to reveal novel host immunomodulatory targets for infection treatment and prevention following severe trauma.

Conclusions

Marshall and Denver scores can reliably predict the susceptibility of trauma patients to MIIEs during their hospital stay. Utilization of these scores could effectively identify patients that would benefit from prophylactic measures to avoid multiple infections and could therefore decrease the high rates of infection-related morbidity and mortality in the trauma population.
Supporting information

S1 Table. Denver score components. (DOCX)

S2 Table. Marshall score components. (DOCX)

S3 Table. Multivariable analysis to find independent predictors of hypersusceptibility to infections (APACHE II). (DOCX)

S4 Table. Multivariable analysis to find independent predictors of hypersusceptibility to infections (ISS). (DOCX)

S5 Table. Multivariable analysis to find independent predictors of hypersusceptibility to infections (NISS). (DOCX)

Author Contributions

Conceptualization: Marianna Almpani, Amy Tsurumi, Laurence G. Rahme.

Data curation: Marianna Almpani, Yashoda V. Dhole, Laura F. Goodfield.

Formal analysis: Marianna Almpani, Thomas Peponis.

Funding acquisition: Laurence G. Rahme.

Investigation: Laurence G. Rahme.

Methodology: Marianna Almpani, Amy Tsurumi, Thomas Peponis, Laurence G. Rahme.

Resources: Ronald G. Tompkins, Laurence G. Rahme.

Supervision: Laurence G. Rahme.

Writing – original draft: Marianna Almpani.

Writing – review & editing: Marianna Almpani, Amy Tsurumi, Thomas Peponis, Yashoda V. Dhole, Laura F. Goodfield, Ronald G. Tompkins, Laurence G. Rahme.

References

1. Krug EG, Sharma GK, Lozano R. The global burden of injuries. Am J Public Health. 2000 Apr; 90(4):523–6. https://doi.org/10.2105/ajph.90.4.523 PMID: 10754963

2. Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients. Arch Surg. 2011 Jul; 146(7):794–801. https://doi.org/10.1001archsurg.2011.41 PMID: 21422331

3. Papia G, McElinan BA, El-Helou P, Louie M, Rachlis A, Szalai JP, et al. Infection in hospitalized trauma patients: incidence, risk factors, and complications. J Trauma. 1999 Nov; 47(5):923–7. https://doi.org/10.1097/00005373-199911000-00018 PMID: 10568723

4. Pories SE, Garnelli RL, Mead PB, Goodwin G, Harris F, Vacek P. The epidemiologic features of nosocomial infections in patients with trauma. Arch Surg. 1991 Jan; 126(1):97–9. https://doi.org/10.1001archsurg.1991.0141025105017 PMID: 1985639

5. Cheadle WG, Wilson M, Hershman MJ, Bergamini D, Richardson JD, Polk HC Jr. Comparison of trauma assessment scores and their use in prediction of infection and death. Ann Surg. 1989 May; 209(5):541–5; discussion 545–6. https://doi.org/10.1097/00000585-198905000-00005 PMID: 2705819

PLOS ONE | https://doi.org/10.1371/journal.pone.0232175 April 29, 2020 12 / 13
6. Hurr H, Hawley HB, Czachor JS, Markert RJ, McCarthy MC. APACHE II and ISS scores as predictors of nosocomial infections in trauma patients. Am J Infect Control. 1999 Apr; 27(2):79–83. https://doi.org/10.1016/s0196-6553(99)70085-4 PMID: 10196483

7. Jamulitrat S, Narong MN, Thongpiyapoom S. Trauma severity scoring systems as predictors of nosocomial infection. Infect Control Hosp Epidemiol. 2002 May; 23(5):268–73. https://doi.org/10.1086/502047 PMID: 12026152

8. Tranca S, Petrisor C, Hagau N, Ciuce C. Can APACHE II, SOFA, ISS, and RTS Severity Scores be used to Predict Septic Complications in Multiple Trauma Patients? J Crit Care Med (Targu Mures). 2016 Aug 10; 2(3):124–30.

9. Olaechea PM, Ulibarrena MA, Alvarez-Lerma F, Insauti J, Palomar M, De la Cal MA;. Factors related to hospital stay among patients with nosocomial infection in the intensive care unit. Infect Control Hosp Epidemiol. 2003 Mar; 24(3):207–13. https://doi.org/10.1086/502191 PMID: 12683514

10. Tsurumi A, Que YA, Ryan CM, Tompkins RG, Rahme LG. TNF-alpha/IL-10 Ratio Correlates with Burn Severity and May Serve as a Risk Predictor of Increased Susceptibility to Infections. Front Public Health. 2016 Oct 5; 4:216. https://doi.org/10.3389/fpubh.2016.00216 PMID: 27761434

11. Yan S, Tsurumi A, Que YA, Ryan CM, Bandyopadhyaya A, Morgan AA, et al. Prediction of multiple infections after severe burn trauma: a prospective cohort study. Ann Surg 2015 Apr; 261(4):781–92. https://doi.org/10.1097/SLA.0000000000000759 PMID: 24950278

12. Inflammation and Host Response to Injury Glue Grant. Infectious and Non-Infectious Complications—Definitions from the Trauma-Related Database (TRDB). http://www.gluegrant.org/PDFs/DefinitionsTRDBInfectComplicationsv102207.pdf.

13. Inflammation and Host Response to Injury Glue Grant. How the Denver Score is Computed. http://www.gluegrant.org/PDFs/Denver_score.pdf.

14. Inflammation and Host Response to Injury Glue Grant. How the Marshall Score is Computed. http://www.gluegrant.org/PDFs/Marshall_score.pdf.

15. Overly FL, Wills H, Valente JH. 'Not just little adults'—a pediatric trauma primer. R I Med J. 2014 Jan 3; 97(1):27–30.

16. Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. JAMA. 2019 May 28; 321(20):2003–2017. https://doi.org/10.1001/jama.2019.5791 PMID: 31104070

17. Chaudry IH, Ayala A. Mechanism of increased susceptibility to infection following hemorrhage. Am J Surg. 1993 Feb; 165(2A Suppl):59S–67S. https://doi.org/10.1016/s0002-9610(05)81208-5 PMID: 8439001

18. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2; 302(21):2323–9. https://doi.org/10.1001/jama.2009.1754 PMID: 19952319

19. Centers for Disease Control and Prevention. Guidelines for the Prevention of Intravascular Catheter-Related Infection. https://www.cdc.gov/hai/pdfs/bsi-guidelines-2011.pdf

20. Singha P, Locklin J, Handa H. A review of the recent advances in antimicrobial coatings for urinary catheters. Acta Biomater. 2017 Mar 1; 50:20–40. https://doi.org/10.1016/j.actbio.2016.11.070 PMID: 27916738

21. Cochrane. Replacing a peripheral venous catheter when clinically indicated versus routine replacement. https://www.cochrane.org/CD007798/PVD_replacing-peripheral-venous-catheter-when-clinically-indicated-versus-routine-replacement

22. Aghaeepour N, Kin C, Ganio EA, Jensen KP, Gaudilliere DK, Tingle M, et al. Deep Immune Profiling of an Arginine-Enriched Nutritional Intervention in Patients Undergoing Surgery. J Immunol. 2017 Aug 9. pii: ji1700421.